MedicaidPrior AuthHigh impact
Change in PDL Status for Hypoglycemics, Insulin and Related Drug Class Effective July 27, 2026
Texas Medicaid·TX · Endocrinology, Family Medicine, Internal Medicine +2 more·Pharmacy
Effective date
Jul 27, 2026
We identified it
Aug 1, 2026
Summary
Effective July 27, 2026, Texas Medicaid (HHSC) has temporarily removed nonpreferred status from Basaglar 100 unit/milliliter KwikPen (NDC 00002771501 and 00002771559) due to Lantus Solostar shipping delays and backorders. Providers can now prescribe these insulin products without obtaining prior authorization, improving patient access to essential medications.
Action Required
By July 27, 2026: Billing team must update billing software to remove prior authorization requirements for Basaglar 100 unit/milliliter KwikPen (NDC 00002771501 and 00002771559) for Texas Medicaid claims. Notify providers and clinical staff that these insulin products no longer require PDL prior authorization. Update pharmacy benefit management system rules and any internal authorization checklists. Failure to remove authorization requirements may cause unnecessary claim delays and patient access issues. Monitor for policy reversal after backorder resolution and be prepared to reinstate nonpreferred status requirements when manufacturer supply normalizes.